Imatinib (Gleevec) Induced Worsening of Pericardial Effusion in CML
Journal Name:
- Fırat Tıp Dergisi
Key Words:
Keywords (Original Language):
Author Name | University of Author | Faculty of Author |
---|---|---|
Abstract (2. Language):
Gleevec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. Gleevec is often associated with edema and occasionally serious fluid retention. Severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking Gleevec, and in 2%-6% of other adult CML patients taking Gleevec. We report a case of a patient with CML and a pericardial effusion worsening after initiating Gleevec.
Bookmark/Search this post with
Abstract (Original Language):
Gleevec (imatinib mesylate), Philadelphia
kromozom
u pozitif kronik fazdaki kronik miyeloid lösemili (KML) erişkin hastanın tedavisinde kullanılmaktadır. Gleevec, sıklıkla ödem ve şiddetli sıvı retansiyonuna neden olur. Gleevec alan ve yeni tanı konulmuş KML'li hastaların %1.3'ünde, erişkin hastaların ise %2-%6'sında sıvı retansiyon reaksiyonu (plevral effüzyon, perikardial effüzyon, pulmoner ödem ve assit gibi) olduğunu bildiren birkaç rapor yayınlanmıştır. Bu çalışmada, Gleevec başlandıktan sonra perikardial effüzyonu artan KML'li hasta rapor edildi.
FULL TEXT (PDF):
- 2
100-101